Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study.
about
Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's diseaseEffects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease.Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease.Certolizumab pegol for the treatment of psoriatic arthritis.[Inflammatory Bowel Disease Competence Network].Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study.Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice.Update on the Medical Management of Crohn's Disease.Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases.Anti-TNF-α therapies for the treatment of Crohn's disease: the past, present and future.A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease.Fungal Infections and New Biologic Therapies.Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease.Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease.Safety Profile of Biologic Drugs in the Treatment of Inflammatory Bowel Diseases: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases.IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy.Substitution with Alternative Anti-TNFα Therapy (SAVANT)-Outcomes of a Crohn's Disease Cohort Undergoing Substitution Therapy with Certolizumab.Early remission status predicts long-term outcomes in patients with Crohn's disease treated with certolizumab pegol.Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study.Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease.Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.Challenges in Using Real-world Clinical Practice Records for Validation of Clinical Trial Data in Inflammatory Bowel Disease: Lessons Learned.Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives.Adherence rates and health care costs in Crohn's disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patient claims and home health nurse data.
P2860
Q31113830-DF072561-7A71-493F-A8F0-1C0B33C407C6Q35559305-D7361F2C-80EE-4962-BD43-CE243450CB51Q36347059-B86FA5C6-2254-4137-A021-8954A5417EC1Q38293774-3130AD6D-6F3C-495D-AE40-B1699C90EBBDQ38344194-0490129B-9FFD-4893-922F-698CA48DF5A2Q38382193-EFAFAB55-7197-40F6-B709-B06CC4F79D0DQ38410616-BBD02295-CEC8-43DF-B6CB-6F81DF5F8829Q38425123-812CC8AA-DA36-451C-B678-6D8C5057B1D8Q38585634-EB793EA9-ACB1-42F6-A03D-205267E36F74Q38630959-CD1EAE71-ACCA-4A02-82DF-5E8467FEBB23Q38652276-4CCE360B-132D-48AD-9C89-B27C815D1D77Q38707864-463C4A79-EBB3-455D-88D4-D2FACB8BF959Q38794862-AF29D147-ECED-4277-A104-E93714E3E84FQ38869663-D41E8918-D673-4D50-9212-3CF75D3BAB11Q38919270-6FB95372-4EF5-40AD-8EE2-BC7046D69825Q38947390-A8B05866-EAEE-461C-AAE3-A8F2347BF0CCQ38972531-6A8E1307-4A34-4FF3-A965-A8FB204ED591Q39032463-047EEC57-EA63-4176-BB4A-2E82CD94B55BQ39830490-6F3D7BC9-2AA2-4AE0-B0F9-08BC3899F9ACQ40634478-8E7ACD13-87BF-48F5-8571-A038309C07FAQ45951213-06E58B32-1F86-4D6F-96E6-77C351F5BE36Q46027208-C15949FE-939B-41F0-827E-9EC5F1531EB2Q46756144-75EF5193-6F44-4BD1-BE35-5406273011EBQ47109861-C25F4CEB-365E-4458-B6B5-0D3C9BB05F20Q47258517-46873480-4524-4695-87E3-8C942B4C9317Q48265479-91D544ED-535E-4EF6-A896-09D8BA7AF9CCQ54961768-B0DF111D-54AA-406E-90BC-44A8327471BAQ55380663-20A7F0FA-A7CA-467D-8EA4-6A4E918BA9FF
P2860
Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Long-term safety and efficacy ...... ults from the PRECiSE 3 study.
@en
type
label
Long-term safety and efficacy ...... ults from the PRECiSE 3 study.
@en
prefLabel
Long-term safety and efficacy ...... ults from the PRECiSE 3 study.
@en
P2093
P2860
P356
P1476
Long-term safety and efficacy ...... ults from the PRECiSE 3 study.
@en
P2093
A Gutierrez
B Pierre-Louis
D A Schwartz
G R Lichtenstein
S Ambarkhane
S Schreiber
P2860
P304
P356
10.1111/APT.12930
P407
P577
2014-08-22T00:00:00Z